Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of Radiolabeled Crenigacestat in Healthy Subjects
NCT02917733Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crenigacestat in solid tumor, lymphoma and leukemia, sponsored by Eli Lilly and Company. Primary endpoint: Urinary and Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered. Started Sep 2016; status: completed.
02
Drugs
crenigacestat
03
Conditions
solid tumorlymphomaleukemia
Beyond the preview
Go deeper on NCT02917733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917733.